Skip to Content
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking abo… Read More
  • Sodium Benzoate Nonsense

    I don’t spend a lot of time on the blog swatting down idiotic ideas about chemicals. It’s a full time job, and (see next post) I already have a full… Read More
  • Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you… Read More
  • A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I… Read More
  • Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground… Read More
Page 1 of 1912345...10...Last »